Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | MPO | P05164 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25868371 | 0.81 | PRMT3 (0.42) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL13328480 | 0.78 | ALDH1A1 (0.46) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL13328482 | 0.77 | ALDH1A1 (0.45) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL13693145 | 0.75 | CA1 (0.57) | ALDH1A1CA1MPOSLC6A4CA12 | |
| SCHEMBL16151568 | 0.75 | ALDH1A1 (0.33) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL475392 | 0.74 | — | — | |
| SCHEMBL8339434 | 0.71 | PRMT3 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12478464 | 0.71 | HTT (0.36) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL23775289 | 0.71 | CA1 (0.37) | CA1MPOSLC6A4CA12CA2 | |
| SCHEMBL13064494 | 0.71 | CA1 (0.40) | CA1MPOSLC6A4CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012064973-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262525-A1 | METHODS OF TREATMENT | ASAH2, FOLH1, CD44 | PRMT3 1324/4885CARM1 806/4885PRMT6 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.